- Home
- IEX vs EXEL Comparison
IEX vs EXEL Comparison
Compare IEX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEX
- EXEL
- Stock Information
- Founded
- IEX 1987
- EXEL 1994
- Country
- IEX United States
- EXEL United States
- Employees
- IEX N/A
- EXEL N/A
- Industry
- IEX Fluid Controls
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IEX Industrials
- EXEL Health Care
- Exchange
- IEX Nasdaq
- EXEL Nasdaq
- Market Cap
- IEX 13.7B
- EXEL 11.3B
- IPO Year
- IEX 1991
- EXEL 2000
- Fundamental
- Price
- IEX $181.25
- EXEL $46.20
- Analyst Decision
- IEX Buy
- EXEL Buy
- Analyst Count
- IEX 8
- EXEL 18
- Target Price
- IEX $220.14
- EXEL $43.00
- AVG Volume (30 Days)
- IEX 710.9K
- EXEL 3.6M
- Earning Date
- IEX 07-30-2025
- EXEL 08-05-2025
- Dividend Yield
- IEX 1.57%
- EXEL N/A
- EPS Growth
- IEX N/A
- EXEL 237.58
- EPS
- IEX 6.30
- EXEL 2.20
- Revenue
- IEX $3,282,600,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- IEX $5.94
- EXEL $9.37
- Revenue Next Year
- IEX $4.07
- EXEL $11.05
- P/E Ratio
- IEX $28.77
- EXEL $20.94
- Revenue Growth
- IEX 1.66
- EXEL 24.49
- 52 Week Low
- IEX $153.36
- EXEL $21.82
- 52 Week High
- IEX $238.22
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- IEX 54.89
- EXEL 59.21
- Support Level
- IEX $173.76
- EXEL $43.32
- Resistance Level
- IEX $183.06
- EXEL $44.48
- Average True Range (ATR)
- IEX 3.63
- EXEL 1.54
- MACD
- IEX 0.62
- EXEL 0.12
- Stochastic Oscillator
- IEX 82.85
- EXEL 47.90
About IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. Based in Lake Forest, Illinois, Idex has manufacturing operations in over 20 countries and has over 7,000 employees. The company generated $3.3 billion in revenue in 2024.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.